IRIS-AR策略的开发:一种提高VTE-PRO随机对照试验入组率和保留率的干预措施
VTE-PRO预试验入组率和保留率低,本研究旨在开发知识转化干预以改善。通过调查参与者障碍并用理论域框架分类,映射至COM-B行为改变轮,形成IRIS-AR干预,含信息手册、每日提醒、家属参与和家庭护理支持。访谈26名关键知情人确认障碍主要为缺乏社会支持和害怕注射,参与者普遍支持多数措施但非全部支持每日提醒。
要点
- VTE-PRO预试验入组率和保留率低,需干预改善。
- IRIS-AR干预包括告知、提醒、参与和支持四部分。
- 参与者支持信息手册、家属参与和家庭护理支持,但非全部支持每日提醒。
核心结论
- IRIS-AR是基于理论和整合知识转化开发的以患者为中心的干预,利用现有项目促进试验参与,可能可适应于改善其他患者导向干预的依从性。
研究设计与样本
- VTE-PRO是一项预试验,评估延长预防对肺癌切除患者静脉血栓栓塞事件的影响,参与者术后30天自我注射低分子量肝素或生理盐水安慰剂,结局包括可行性、静脉血栓栓塞发生率及相关发病率和死亡率。
- 本研究通过调查合格参与者识别参与障碍,使用理论域框架分类,映射至COM-B行为改变轮以识别支持入组和保留的潜在干预,并对患者进行关键知情人访谈以完善和确认障碍及IRIS-AR的可接受性,获机构审查委员会批准。
主要发现
- 访谈了26名关键知情人参与者,参与试验的最常见障碍包括缺乏社会支持和害怕针头注射。
- 参与者普遍支持使用信息手册、家属/照护者参与和家庭护理项目支持,但并非所有人都支持使用每日提醒。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Venous Thromboembolism Prophylaxis (VTE-PRO) randomized trial is a pilot study evaluating the impact of extended-duration prophylaxis on venous thromboembolic events in patients undergoing lung cancer resection. Enrolled VTE-PRO participants self-inject either low-molecular weight heparin or a saline placebo for 30 days postoperatively. Study outcomes include feasibility, incidence of venous thromboembolism, and venous thromboembolism-related morbidity and mortality. Initial analyses demonstrated low rates of accrual and retention for the VTE-PRO pilot. Therefore, the purpose of the current study was to develop a knowledge translation intervention to improve VTE-PRO pilot trial accrual and retention. METHODS: Eligible participants were surveyed to identify the barriers to VTE-PRO participation. The Theoretical Domains Framework was used to categorize these barriers. Barriers were mapped to the capabilities, opportunities, and behavior (COM-B) behavioral change wheel to identify potential interventions to support trial accrual and retention. The resulting knowledge translation intervention was titled Inform, Remind, Involve and Support to improve Accrual and Retention (IRIS-AR). Key informant interviews with patients were held to refine and confirm the validity of identified barriers and perceived acceptability of the proposed IRIS-AR intervention. Institutional Review Board approval was granted for this study. RESULTS: The resulting intervention included: information booklets and counseling sessions to identify unique participant challenges to trial participation (Inform); daily reminders to administer injections (Remind); involvement of family/caregivers in study processes (Involve); and leverage of an existing home-care nursing program to provide injection support when needed (Support). Twenty-six key informant participants were interviewed. The most common barriers to trial participation included lack of social support and fear of needle injection. Participants generally supported use of information booklets, involvement of family/caregivers, and support by a home-care nursing program; however, not all supported the use of daily reminders. CONCLUSION: Developed using theory and integrated knowledge translation, the IRIS-AR presents a patient-centered intervention that leverages existing programs to promote trial engagement. The proposed strategy can likely be adapted to improve compliance with other patient-directed interventions. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02334007 . Registered on 8 January 2015.
引用
- Fahim C, Hylton D, Simunovic M, et al. Development of the IRIS-AR strategy: an intervention to improve rates of accrual and retention for the VTE-PRO randomized controlled trial. Trials. 2019. PMID: 31324209. doi:10.1186/s13063-019-3536-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。